nach oben

Erschienen in:

21.09.2019 | Original Paper

Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women’s Health Initiative Observational Study

verfasst von: Britton Trabert, Sally B. Coburn, Roni T. Falk, JoAnn E. Manson, Louise A. Brinton, Margery L. Gass, Lewis H. Kuller, Thomas E. Rohan, Ruth M. Pfeiffer, Lihong Qi, Marcia L. Stefanick, Nicolas Wentzensen, Garnet L. Anderson, Xia Xu

Erschienen in: Cancer Causes & Control | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Menopausal hormone therapy (MHT) use induces alterations in circulating estrogens/estrogen metabolites, which may contribute to the altered risk of reproductive tract cancers among current users. Thus, the current study assessed associations between circulating estrogens/estrogen metabolites and ovarian and endometrial cancer risk among MHT users.

Methods

We conducted a nested case–control study among postmenopausal women using MHT at baseline in the Women’s Health Initiative Observational Study (179 ovarian cancers, 396 controls; 230 endometrial cancers, 253 controls). Multivariable logistic regression was utilized to estimate odds ratios and 95% confidence intervals overall and by subtype.

Results

Estrogen/estrogen metabolite levels were not associated with overall or serous ovarian cancer risk, examined separately. However, unconjugated estradiol was positively associated with non-serous ovarian cancer risk [quintile 5 vs. quintile 1: 3.01 (1.17–7.73); p-trend = 0.03; p-het < 0.01]. Endometrial cancer risk was unrelated to estrogen/estrogen metabolite levels among women who took combined estrogen/progestin therapy (EPT).

Conclusions

These findings provide novel evidence that may support a heterogeneous hormonal etiology across ovarian cancer subtypes. Circulating estrogens did not influence endometrial cancer risk among women with EPT-induced high-estrogen levels. Larger studies are needed to delineate the relationship between ovarian/endometrial cancer subtypes and estrogen levels in the context of MHT use.

Trabert B et al (2012) Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 107(7):1181–1187CrossRefPubMedPubMedCentral

Collaborative Group on Epidemiological Studies of Ovarian et al (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385(9980):1835–1842.CrossRef

Trabert B et al (2013) Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 132(2):417–426CrossRefPubMed

Trabert B et al (2016) Circulating estrogens and postmenopausal ovarian cancer risk in the Women’s Health Initiative Observational Study. Cancer Epidemiol Biomark Prev 25(4):648–656CrossRef

Brinton LA et al (2016) Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol Biomark Prev 25(7):1081–1089CrossRef

Schock H et al (2014) Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr Relat Cancer 21(6):831–844CrossRefPubMedPubMedCentral

Dallal CM et al (2016) Estrogen metabolism and risk of postmenopausal endometrial and ovarian cancer: the B~FIT cohort. Horm Cancer 7(1):49–64CrossRefPubMedPubMedCentral

Zeleniuch-Jacquotte A et al (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84(7):975–981CrossRefPubMedPubMedCentral

Lukanova A et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108(3):425–432CrossRefPubMed

10.

Helzlsouer KJ et al (1995) Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274(24):1926–1930CrossRefPubMed

11.

Lukanova A et al (2003) Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer 104(5):636–642CrossRefPubMed

12.

Falk RT et al (2019) Estrogen metabolism in menopausal hormone users in the women’s health initiative observational study: does it differ between estrogen plus progestin and estrogen alone? Int J Cancer 144(4):730–740CrossRefPubMed

13.

Anderson G et al (1998) Design of the women’s health initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 19(1):61–109.

14.

Langer RD et al (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13(9 Suppl):S107–S121CrossRefPubMed

15.

Xu X et al (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 79(20):7813–7821CrossRefPubMed

16.

Loud JT et al (2014) Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat 143(3):517–529CrossRefPubMedPubMedCentral

17.

Gates MA et al (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171(1):45–53CrossRefPubMed

18.

Yang HP et al (2012) Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer 131(4):938–948CrossRefPubMed

19.

Fortner RT et al (2015) Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. Int J Cancer 137(5):1196–1208CrossRefPubMedPubMedCentral

20.

Pearce CL et al (2013) Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomark Prev 22(5):880–890CrossRef

21.

Pearce CL et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4):385–394CrossRefPubMedPubMedCentral

22.

Chang SC et al (2007) Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomark Prev 16(4):723–730CrossRef

23.

Karageorgi S et al (2010) Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976–2004. Int J Cancer 126(1):208–216CrossRefPubMedPubMedCentral

24.

Allen NE et al (2008) Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 15(2):485–497CrossRefPubMedPubMedCentral

25.

Newbold RR, Liehr JG (2000) Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 60(2):235–237PubMed

26.

Wentzensen N et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 34(24):2888–2898CrossRefPubMedPubMedCentral

Titel: Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women’s Health Initiative Observational Study
verfasst von: Britton Trabert
Sally B. Coburn
Roni T. Falk
JoAnn E. Manson
Louise A. Brinton
Margery L. Gass
Lewis H. Kuller
Thomas E. Rohan
Ruth M. Pfeiffer
Lihong Qi
Marcia L. Stefanick
Nicolas Wentzensen
Garnet L. Anderson
Xia Xu
Publikationsdatum: 21.09.2019
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 11/2019
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-019-01233-8

Springer Medizin

Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women’s Health Initiative Observational Study